Scleroderma: features of the current and possibility treatments. Review references
Abstract
Data from various references about features of a current limited склеродермии (OS) is presented interfaced. The hypothesis that OS and system scleroderma (SSD) represent versions of one pathological process that proves to be true presence an one-orientation of metabolic shifts, a generality skin changes at both forms of illness, and also cases of transformation of the localised process in a progressing system sclerosis Is discussed. Frequency of occurrence, prevalence of those or other forms of OS, longevity of patients, clinical displays and duration of a current of OS and its communication with other pathological processes is discussed. Various schemes of treatment of OS which have multicourse and multicomponent character are considered.
About the Authors
G. E. Gursky
Rostov State Medical University
Russian Federation
Russian Federation
Department of Skin and Venereal Diseases
29 Nakhichevansky st., Rostov-on-Don, 344022
V. A. Grebennikov
Rostov State Medical University
Russian Federation
Russian Federation
Department of Skin and Venereal Diseases
29 Nakhichevansky st., Rostov-on-Don, 344022
V. V. Horonko
Rostov State Medical University
Russian Federation
Russian Federation
Department of Pharmacology and Clinical Pharmacology
29 Nakhichevansky st., Rostov-on-Don, 344022
References
1. Гусева Н. Г. Системная склеродермия: клиника, диагностика, лечение // Рос. журн. кож. и вен. болезней. – 2002. – № 4. - С. 5–15.
2. Connolly M.K. Pulmonary Arterial Hypertension in Scleroderma: A New Treatment// «Scleroderma Voice». – 2002. – № 2 // www.scleroderma.org/medical/pulmonary_articles/ Connolly_2002.shtm – 32k.
3. Sjogren RW. Gastrointestinal features of scleroderma // Curr Opin Rheumatol. – 1996. – Nov;8(6):569-75. // www.ncbi.nlm.nih.gov/pubmed/9018461.
4. Pathak R. Gabor A.J. Scleroderma and central nervous system vasculitis// Stroke. – 1991. – Vol 22. – P. 410–413.
5. Галлямова Ю.А. Очаговая склеродермия// Лечащий врач. – 2008. – № 05// www.lvrach.ru/doctore/2008/05/5157128/ – 59k.
6. Zulian F. Systemic manifestations in localized scleroderma // Current Rheumatology Reports. – 2004. – Volume 6, Number 6. – P. 417–424.
7. Болотная Л.А., Сербина И.М. Современная патогенетическая терапия склеродермии // «Международный медицинский журнал». – 1999. - № 3. – С. 56–58.
8. Коробейникова Э.А., Мартынова Л.М., Анисимова А.В. Клинические аспекты ограниченной склеродермии // Рос. журн. кожн. и вен. бол. – 2004. – № 3. – С. 27–29.
9. Furst A. Scleroderma: a fascinating, troubling disease // Advanced Practice Nursing journal. – 2004. – № 4 (2).
10. Болотная Л.А., Шахова Ф.Б., Сербина И.М. Новое в патогенезе и терапии ограниченной склеродермии// II Вестн. дерматол. венерол. – 2004. - № 2. – С. 31–34.
11. Alexandrescu D.T., Bhagwati N. S., Wiernik P. H. Chemotherapy-induced scleroderma: a pleiomorphic syndrome// Clinical and Experimental Dermatology. – 22 Feb 2005. – Volume 30 Issue 2. – P. 141–145.
12. Gliddon AE et al., Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. // Arthritis Rheum. – 2007. – Nov;56(11):3837-46.
13. Довжанский С. И. Клинико-иммунологические параллели при ограниченной и системной склеродермии // Рос. журн. кожн. и вен. бол. – 2002. ж № 4. – С. 26–29.
14. Asano Y., Ihn H., Jinnin M., Mimura Y., Tamaki K. Involvement of v5 Integrin in the Establishment of Autocrine TGF-Signaling in Dermal Fibroblasts Derived from Localized Scleroderma// Journal of Investigative Dermatology. – 2006. – №126. – P. 1761–1769.
15. Milenkovica S., Petrovicc L., Risimica D., et al. Choroidal Sclerosis in Localized Scleroderma (Morphea en Plaque)// Ophthalmic Res. – 2008. – № 40. P. 101–104.
16. Carlson J.A., Chen, Ko-Ron, Cutaneous Vasculitis Update: Neutrophilic Muscular Vessel and Eosinophilic, Granulomatous, and Lymphocytic Vasculitis Syndromes// The American Journal of Dermatopathology. – February 2007. – Volume 29, Issue 1. – P. 32–43.
17. Потекаев Н.С., Потекаев Н.Н. Болезнь Лайма и обусловленные ею поражения кожи // Вестник дерматологии и венерологии. – 2006. – № 6. – С. 3–9.
18. Bonifati C, Impara G, Morrone A, Pietrangeli A, Carducci M. Simultaneous occurrence of linear scleroderma and homolateral segmental vitiligo // J Eur Acad Dermatol Venereol. – 2006. – № 20 (1): 63–5.
19. Christen-Zaech S.; Hakim M. D.; Afsar F.S., Paller A.S., Pediatric morphea (localized scleroderma): Review of 136 patients// Journal of the American Academy of Dermatology. – September 2008. – Volume 59, Issue 3. – P. 385–396// www.journals.elsevierhealth.com/periodicals/ymjd/article/PIIS01909622080... – 35k.
20. Dehen L, Roujeau JC, Cosnes A, et al. Internal involvement in localized scleroderma // Medicine (Baltimore). – 1994. – V. 73. – P. 241–245.
21. González-López MA, Drake M, González-Vela MC, Armesto S, Llaca HF, Val-Bernal JF. Generalized morphea and primary biliary cirrhosis coexisting in a male patient // J. Dermatol. – 2006. – V.33 (10): 709–13.
22. Göring HD, Panzner M, Lakotta W, Ziemer A. Coincidence of scleroderma and primary biliary cirrhosis. Results of a systematic study of a dermatologic patient sample// Hautarzt. – 1998, May. – V.49(5). – P. 361–366.
23. Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma // Arthritis Rheum. – 2004. – V. 50 (1). – P. 227–232.
24. Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease // Arthritis & Rheumatism. – 2005. – V. 52. – P. 2872–2881.
25. Laxer RM, Feldman BM. General and local scleroderma in children and dermatomyositis and associated syndromes. // Curr Opin Rheumatol. – 1997 Sep. – V. 9(5). – P. 458–464.
26. Laxer RM, Zulian F. Localized scleroderma // Curr Opin Rheumatol. – 2006. – V. 18 (6). – P. 606–613.
27. Peterson LS, Nelson AM, Su WPD. Classification of morphea (localized scleroderma) // Mayo Clin Proc. – 1995. – V. 70. – P. 1068–1076.
28. Болотная Л.А., Сербина И.М. Современная патогенетическая терапия склеродермии // Международ. мед. Журнал. – 1999. – № 3. – C. 56–58.
29. Смирнов А.В., Курников Г.Ю., Пересторонина В.С. КВЧ-терапия в лечении ограниченной склеродермии // Миллиметровые волны в биологии и медицине. – 2000. – № 2(18). - C. 34–35.
30. Коколина В.Ф., Харыбина Е.И., И.Л., Уколова Е.С.Киреева Клинико-иммунологические особенности и модификация комплексного лечения при очаговой склеродермии наружных гениталий у девочек с помощью курсовой низкоинтенсивной лазерной терапии // Педиатрия. – 2001. – № 3. – C. 106–108.
31. Gruss,-C-J; Von-Kobyletzki,-G; Behrens-Williams,-S-C et al. Effects of low dose ultraviolet A-1 phototherapy on morphea» // Photodermatol-Photoimmunol-Photomed. – 2001 Aug. – V. 17(4). – P. 149-55
32. Kreuter,-A; Gambichler, -Т; Avermaete, A. et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea // Pediatr-Dermatol. – 2001 May-Jun. – V.18 (3). – P. 241–245.
33. Gliddon AE, Doré CJ, Black CM et al., Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. // Arthritis Rheum. – 2007, Nov. – V. 56(11). – P. 3837–3846.
34. Bruns A., Lacerda C.G., de Assis Goulart L.S., Trevisani V.M.F. The treatment of localized scleroderma in childhood // Pediatric Rheumatology Online Journal// www.pedrheumonlinejournal.org/SeptOct/pdf/localized%20scleroderma.pdf.
35. Cassidy JT, Petty RE: The sclerodermas and related disease. // Textbook of Pediatrics Rheumatology. – 4th ed. – Philadelphia, Pennsylvania, W.B. Saunders. – 2001. – P. 505–541.
36. Unterberger I., Trinka E, Engelhardt K, A Muigg1, P Eller1, M Wagner3, N Sepp2, G Bauer1 . Linear scleroderma «en coup de sabre» coexisting with plaque-morphea: neuroradiological manifestation and response to corticosteroids // Journal of Neurology Neurosurgery and Psychiatry. – 2003. – V.74. – P. 661–664.
37. Kreuter A., Gambichler T., Breuckmann F., et al. Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate in Severe Localized Scleroderma// Arch Dermatol. – 2005. – V. 141. – P. 847–852.
38. Falanga V, Medsger TA: D-пеницилламин in the treatment of localized scleroderma // Arch Dermatol. – 1990. – V.126. – P. 609–612.
39. Hilário MO. Esclerodermia. //Oliveira SK, Azevedo EC. Reumatologia Pediátrica. – Rio de Janeiro: Revinter, 2000, p295.
40. Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxer RM: MTX and corticosteroid therapy for pediatric localized scleroderma // J Pediatr. – 2000. – V. 136(1). – P. 91–95.
41. Cunningham BB; Landells IDR, Langman C, et al: Topical calcipotriene for morphea/linear scleroderma // J Am Acad Dermatol. – 1998. – V.39. – P. 211–215.
42. Eubanks LE, Mc Burney EI, Galen W, Reed R: Linear Scleroderma in Children // Int J Dermatol. – 1996. – V.35(5). – P. 330–336.
43. Kerscher M, Volkenandt M, Gruss C, et al: Low-dose UVA1 phototherapy for treatment of localized scleroderma // J Am Acad Dermatol. – 1998. – V.38. – P. 21–26.
44. Kochanek KS, Goldermann R, Lehmann, et al: PUVA phototherapy in disabling pansclerotic morphea of children. – 1995, p 423.
45. Gruss C, Stucker M, Von Kobyletzki G, et al: Low-dose UVA1 phototherapy in disabling pansclerotic morphea of childhood // Br J Dermatol. – 1997. – V.136. – P. 293–294.
46. Kreuter A, et al: Linear scleroderma “en coup de sabre” treated with topical calcipotriol and psoralen plus UVA // J Eur Acad Dermatol Venereol. – 2003. – V.17(5). – P. 601–602.
47. Kreuter A, et al: Combined treatment with Calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea // Pediatric Dermatology. – 2001. – V.18(3). – P. 241–245.
48. Walch F, Ullrich H, Schitz G, et al: Treatment of severe localized scleroderma by plasmapheresis – report of three cases // Br J Dermatol. – 1995. – V.133. – P. 605–609.
49. Lam G.K., Hummers L.K., Woods A., Wigley F.M. Efficacy and Safety of Etanercept in the Treatment of Scleroderma-Associated Joint Disease// J.Reumatol. vol. 34: NO. 7 july 2007.
50. Oliver SJ, Moreira A, Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide.// Clin Immunol. 2000 Nov;97(2):109-20.
51. Man J. Dytoc M.T. Use of Imiquimod Cream 5% in the Treatment of Localized Morphea // Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology. Volume 8, Number 3 / Июнь 2004 г.
Review
For citations:
Gursky G.E., Grebennikov V.A., Horonko V.V. Scleroderma: features of the current and possibility treatments. Review references. Medical Herald of the South of Russia. 2011;(1):4-9. (In Russ.)
Views:
580
Email this article 